www.ijpsonline.com
Special Issue 2, 2020 Indian Journal of Pharmaceutical Sciences
35
*Address for correspondence
E-mail:
[email protected]
Differential Expression of ANXA2 in Eutopic and Ectopic
Endometrium
HAIYAN YU, QINGLING LU1, YITING WANG1, X. MA, BO LI1 AND LINA YANG1*
Health Management Center, 1Department of Gynecology, Heilongjiang Provincial Hospital, Harbin City, 150036, Heilongjiang
Province, China
Yu et al.: Differential Expression of ANXA2 in Eutopic and Ectopic Endometrium
The purpose of this study was to compare the differences in expression of annexin A2 between eutopic and
ectopic endometria and to explore the pathogenesis of adenomyosis. In this study, 22 adenomyosis patients
who underwent uterine laparotomy in Heilongjiang Provincial Hospital from April 2016 to October 2018
were enrolled as the observation group. The eutopic and ectopic endometria were used for the experiment.
In addition, 22 uterine fibroids patients with normal endometrium who underwent open hysterectomy were
selected as the control group. The levels of annexin A2 in endometrial tissue and serum were compared
between the two groups. The results showed that the annexin A2 level in normal endometrial tissue was
significantly lower than that in the eutopic and ectopic endometrial tissue and the annexin A2 level in the
ectopic endometrium was significantly higher than that in the eutopic endometrium (p<0.05). The annexin
A2 level in the serum of the observation group was significantly (p<0.05) higher than that of the control
group. Clinical monitoring of changes in annexin A2 level could be useful as auxiliary diagnostic marker to
start treatment of adenomyosis, so as to project prognostic changes more accurately. However, the results
of this study still need to be verified with multi-center samples.
Key words: Annexin A2, eutopic endometrium, ectopic endometrium, expression difference, adenomyosis
Adenomyosis (AM) mainly refers to a type of disease in
which benign infiltration and growth occur constantly
in the glands or interstitium of the endometrium
towards the muscular layer, causing symptoms such as
dysmenorrhea or excessive menstruation [1]. This is an
estrogen-dependent disease that can be pathologically
benign. However, some biological behaviors, such as
implantation, infiltration and recurrence of malignant
tumors have a great impact on patients’ quality of life[2-4].
Detection of serum CAl25 is helpful for diagnosis, but
final diagnosis still requires surgery and patholog y.
Due to the lack of reliable diagnostic indicators, it
is inevitable to misdiagnose or miss the diagnosis.
Therefore, it is of great significance to search for a
diagnostic marker. In addition, moderate and severe
dysmenorrhea seriously affects the physical and mental
health and quality of life of women of childbearing age
but the relevant mechanism is still not very clear and
the root cause urgently needs to be investigated.
Annexin A2, also known as Annexin II, AXII and
ANXA2. ANXA2 is more commonly expressed in
human endothelial cells, neutrophils, bone marrow
www.ijpsonline.com
Special Issue 2, 2020Indian Journal of Pharmaceutical Sciences
36
cells, brain cells and some tumor cells. It is highly
expressed in cells with high proliferation and
differentiation ability, and is expressed in cells with
low differentiation. About 1/3rd of ANXA2 is produced
by endothelial cells, which play a very important role
in the cells in and out of the body [5]. Within the cell,
it is responsible for cell proliferation, differentiation,
apoptosis, DNA synthesis, RNA binding, mRNA
transport, cytoskeletal remodeling and stabilization,
biofilm formation, vesicle trafficking. Outside the cell,
it is responsible for osteoblast formation and bone
resorption, channel formation of Ca 2+, opening and
regulation of ion flux frequency, signal transduction,
immunoglobulin transport, cell metastasis and invasion,
epithelial mesenchymal transition (EMT), fibrinolysis,
and the formation of new blood vessels. And in many
diseases, such as human immunodeficiency virus
(HIV), hepatitis B, hepatitis C, diabetic nephropathy,
thyroid disease, sepsis, endometriosis, melanoma,
psoriasis, keloid, acute young granulocyte leukemia,
lymphoma, multiple myeloma, acute promyelocytic
leukemia, lupus nephritis and malignant tumor, it also
plays a very important role. In addition, it can serve as
a specific anchor protein for bacteria and viruses and
is also involved in the regulation of redox reactions in
cells[6-8].
It was found that estrogen in the female could
significantly regulate the expression of ANXA2,
which could affect the incidence of AM by means of
endometrial metastasis and angiogenesis. In recent
years, it was reported that the EMT is the initiator of the
pathogenesis of AM [9]. Studies on in vitro AM model
confirmed that estrogen can significantly up-regulate
ANXA2 and induce the occurrence of EMT, suggesting
that ANXA2 may be related to the occurrence of AM.
Some studies have also confirmed that ANXA2 plays
an active role in AM development by endometrial
metastasis and angiogenesis. In this study, the
expression of ANXA2 in AM tissues and serum of
the eutopic endometrium and ectopic endometrium
was detected by immunohistochemical S-P assay
and enzyme-linked immunosorbent assay (ELISA)
to explore its mechanism of action in the occurrence
and development of AM, so as to provide a reliable
theoretical basis for the clinical diagnosis and treatment
of AM and the development and application of relevant
markers.
From April 2016 to October 2018, 22 AM patients,
aged 31-46 y, with an average age of 42.55±4.82 y,
who underwent laparoscopic hysterectomy in the
Heilongjiang Provincial Hospital were enrolled as the
observation group. The eutopic and ectopic endometria
were used for experiments. Thirty two preoperative
patients with synchronous uterine fibroids were
selected, the patients were aged 33-47 y, with an average
age of 43.64±5.65 y. All of them were confirmed to
have uterine fibroids and normal endometrium on
postoperative pathology.
During the same period, 22 cases of normal endometrium
in patients with uterine fibroids undergoing laparoscopic
hysterectomy in the Heilongjiang Provincial Hospital
were selected, who were aged from 32 to 46 y, with an
average age of 42.60±4.74 y as the control group. Thirty-
two preoperative serums of patients with synchronous
uterine fibroids were selected. The patients were 33
to 48 y, with an average of 44.02±5.95 y. All of them
were confirmed to have uterine fibroids and normal
endometrium by postoperative pathology.
All specimens were strictly screened as premenopausal
women with no endometrial atypical hyperplasia. The
patient should have no other endocrine, immune and
metabolic diseases, malign ant tumors, and did not
receive any hormone or immunotherapy within 3 mo
before surgery. This study was approved by the medical
ethics committee of the Heilongjiang Provincial
Hospital, all patients were informed and gave consent
to the content of this study and all pathological sections
were reviewed by the pathologist.
In this study, the tissue was excised by paraffin
embedding surgery and stained with a 4 μm thick
section. All specimens were operated according to kit
instructions under the same conditions, and PBS was
used as negative control instead of primary antibody.
The specific operation process is shown in fig. 1.
The specific reaction of antigen and antibody is used
to connect the substance to enzyme and then the color
reaction is produced between enzyme and substrate for
quantitative determination. The subject to be measured
may be an antibody or an antigen. The method of labeling
with fluorescein is called immunofluorescence and the
commonly used luciferin is fluorescein isothiocyanate,
rhodamine and so on. The commonly used enzyme is
horseradish peroxidase. The enzyme reacts with the
substrate to form an opaque deposit, which shows the
position of the presence of the antigen. In this study,
3 ml of venous blood was taken on an empty stomach
in the morning before the open hysterectomy and the
serum was separated and stored at –80°. The enzyme
labeling instrument was Bio-Rad680 product (Bio-Rad,
www.ijpsonline.com
Special Issue 2, 2020 Indian Journal of Pharmaceutical Sciences
37
USA). The procedure described in the kit was followed
strictly during testing.
The data were processed by SPSS20.0 statistical
software and the measurement data were expressed as
mean±standard deviation. t test was used to compare
serum concentrations between groups, and p<0.05 was
considered statistically significant.
Studies have found that the promotion of endometrial
tissue growth, distant metastasis and angiogenesis
in AM patients is achieved through the mechanism
of ANXA2-induced EMT. The basic structure of
ANXA2 contains 339 amino acids, consisting of a
3kD N-terminus and a 33kD C-terminal domain. As
a calcium-binding cytoskeleton protein, it is involved
in angiogenesis, proliferation, apoptosis, transduction
of calcium signal and cell growth regulation. The
mechanism of its induction of EMT in AM may be that
it is hydrolyzed into fibrinolytic enzyme after binding
to fibrinolytic progenitor and fibrinolytic enzyme has
the function of degrading extracellular matrix and
basement membrane of peripheral blood vessels. It
can also bind to adhesion molecules on the surface of
cell, so as to change the adhesion between cells and
between cells and matrix, enhance the antiapoptotic
ability and motor ability of cells and develop EMT. The
levels of ANXA2 in the endometrial tissues of the two
groups were compared. It was found that the level of
ANXA2 in the normal endometrial tissue of the control
group was significantly lower than that in the ectopic
and the eutopic endometrium tissue in the observation
group (p<0.05) and the level of ANXA2 in the ectopic
endometrial tissue was significantly higher than that in
the eutopic endometrial tissue (p<0.05), as shown in
Table 1 and fig. 2.
ANXA2 is a calcium-mediated phospholipid-binding
protein, a member of the membrane protein family,
widely distributed in the nucleus, cytoplasm and
cytoplasmic membrane surface. In cells, ANXA2 is
involved in a series of important life processes including
membrane formation, membrane transport, endocytosis,
exocytosis, cell proliferation, signal transduction,
differentiation and apoptosis. In patients with elevated
AM, estrogen might increase cyclooxygenase 2 by up-
regulating ANXA2, thereby increasing the production
of prostaglandin E2 and promoting the production and
exacerbation of dysmenorrhea. EMT is also closely
related to the high estrogen environment, and estrogen-
induced EMT is one of the important mechanisms of
AM development, in which ANXA2 may play a key
role. In this study, the ANXA2 level in serum in the
observation group was significantly higher than that in
the control group, and the difference between the two
groups was statistically significant (p<0.05), as shown
in Table 2. This suggested that the level of ANXA2 in
serum was also significantly increased in patients with
AM, which may be related to the fact that the level of
ANXA2 was up-regulated by the disorder of estrogen
metabolism in patients.
Conventional xylene
dewaxing and gradient
alcohol dehydration; xylene
Ⅰ 20 min, xylene Ⅱ20 min,
100% alcohol 10 min, 100%
alcohol 10 min, 95% alcohol
5 min, 80% alcohol 5 min,
70% alcohol 5 min
Bake slices at 68° for 20 minutes
DAB/H2O2 reactive dyeing and full
rinsing of tap water; Hematoxylin re-
dyeing, conventional dehydration,
transparency, drying, sealing
Blocking the inactivation of
endogenous peroxidase:
incubating at 3% H2O2 37°
for 10 minutes, rinsing with
PBS for 3*5 minutes
Antigen repair: boil in
0.01M citric acid buffer
(PH6.0) for 15 - 20 minutes
(95°), then rinse the
cylinder with cold water to
accelerate cooling to room
temperature, and rinse with
PBS for 3*5 minutes
Normal sheep serum
working fluid was sealed at
37° for 10 minutes, and
dumped without washing.
Drip streptomycin-
ovalbumin working solution
labeled with horseradish
peroxidase, incubate at 37 °
for 30 minutes, and rinse
with PBS for 3*5 minutes
Drop the first antibody and
incubate overnight in
refrigerator at 4 °. and rinse
the PBS for 3*5 min (PBS
buffer instead of the first
antibody as negative
control);
The second antibody was
labeled with biotin,
incubated at 37° for 30
minutes and washed with
PBS for 3*5 minutes.
Fig. 1: S-P staining flow chart
www.ijpsonline.com
Special Issue 2, 2020Indian Journal of Pharmaceutical Sciences
38
ANXA2 was found to be abnormally expressed in
cervical cancer, ovarian cancer, choriocarcinoma
and other gynecological malignancies. AM also had
similar biological behavior to malignant tumors.
It was speculated that ANXA2 may be abnormally
expressed in human AM and promote the occurrence
and development of AM, but relevant studies have not
been reported. The level of ANXA2 in peripheral blood
of patients with uterine fibroids was significantly lower
than that of patients with AM (p<0.05). This indicated
that the level of ANXA2 in peripheral blood had a
certain differentiation effect between AM and uterine
fibroids, suggesting that ANXA2 may be a new marker
for AM diagnosis. Therefore, changes in the level of
ANXA2 need to be monitored to assist in the diagnosis
and treatment of patients with AM.
AM mostly occurs in middle-aged women and its
main clinical symptoms are secondary dysmenorrhea
and increased menstrual volume, as well as infertility.
Currently, hysterectomy is the most effective treatment
option. However, this surgical method is often hard
to accept for some patients who have fertility needs
or desire to retain the uterus and the most accurate
means of diagnosis nowadays is postoperative
histopathological examination. Therefore, it is of great
significance to search for an early biomarker to evaluate
AM. It has been reported that the incidence of AM
may be related to EMT and ANXA2 could induce this
transformation mechanism. ANXA2, as the co-receptor
of tissue plasminogen activator and plasminogen, can
be produced by plasminogen mediated and catalyzed by
cell surface layer. In endothelial cells, mononuclear or
macrophages, and some tumor cells, it can participate
in biological membrane and ion channels, cytoskeleton,
cell proliferation, differentiatio n, and other processes,
which are associated with endometrial lesions.
The results of this study showed that the level of ANXA2
in the normal endometrial tissue was significantly lower
than that in the eutopic and ectopic endometria (p<0.05),
suggesting that the level of ANXA2 in the endometrial
tissue of patients with AM was significantly increased.
This could be related to the involvement of ANXA2 in
the pathogenesis and progression of AM. As a calcium-
binding cytoskeletal protein, ANXA2 can regulate the
growth, proliferation, and apoptosis of cells or blood
Group Cases ANXA2
Control group Normal endometrium 22 3.80±2.62
Observation
group
Eutopic endometrium 22 7.88±2.04
Ectopic endometrium 22 8.42±1.98
TABLE 1: COMPARISON OF ANXA2 LEVELS IN
ENDOMETRIAL TISSUE BETWEEN THE TWO
GROUPS
Mean±standard deviation, ng/ml
(a)
(b)
(c)
Fig. 2: Expression of ANXA2 in the intimal tissue of two groups
of patients
(a) Expression of ANXA2 in ectopic endometrium of patients
with adenomyosis. (b) Expression of ANXA2 in the eutopic
endometrium of patients with adenomyosis. (c) Expression of
ANXA2 in normal endometrium
Group Cases ANXA2
Control group 22 7.78±2.11
Observation group 22 8.28±1.72
t - 2.562
P - ˂0.05
Adenomyosis group 32 3.14±0.52
Fibroid group 32 1.04±0.28
t - 20.774
P - ˂0. 05
TABLE 2: COMPARISON OF ANXA2 LEVELS IN
SERUM OF TWO GROUPS OF PATIENTS
Mean±standard deviation, ng/ml
www.ijpsonline.com
Special Issue 2, 2020 Indian Journal of Pharmaceutical Sciences
39
kappa B alpha are regulated by estradiol in endometrial cells.
Turk J Obstet Gynecol 2018;15(1):50-9.
4. Zou Y , Liu FY , Wang LQ. Downregulation of DNA
methyltransferase 3 alpha promotes cell proliferation and
invasion of ectopic endometrial stromal cells in adenomyosis.
Gene 2017;604:41-7.
5. Lin X, Dai Y , Xu W. Hypoxia Promotes Ectopic Adhesion
Ability of Endometrial Stromal Cells via TGF-β1/Smad
Signalling in Endometriosis. J Endocrinol 2018;159(4):1630-
41.
6. Ji F, Yang X, He Y . Aberrant endometrial DNA methylome
of homeobox A10 and catechol-O-methyltransferase in
endometriosis. J Assist Reprod Genet 2017;34(3):409-15.
7. Patel BG, Rudnicki M, Yu J, Shu Y , Taylor RN. Progesterone
resistance in endometriosis: origins, consequences and
interventions. Acta Obstet Gynecol Scand 2017;96(6):623-32.
8. Zhao L, Gu C, Ye M, Zhang Z, Li L, Fan W, et al. Integration
analysis of microRNA and mRNA paired expression profiling
identifies deregulated microRNA-transcription factor-gene
regulatory networks in ovarian endometriosis. Reprod Biol
Endocrinol 2018;16(1):4.
9. Guo SW. Fibrogenesis resulting from cyclic bleeding: the
Holy Grail of the natural history of ectopic endometrium. Hum
Reprod 2018;33(3):353-6.
vessels and the conduction of calcium signals and can
be hydrolyzed into fibrinolytic enzyme by combining
with plasminogen, resulting in the degradation of
extracellular matrix and vascular basement membrane.
In addition, it can be combined with adhesion
molecules on the cell surface, leading to changes in
adhesion between cells and the matrix, strengthening
the antiapoptosis and motor ability of cells themselves,
and eventually causing AM.
In this study, for the first time, ANXA2 in serum of
patients with AM was determined using ELISA before
surgery and it was significantly higher than that in
patients with uterine fibroids, suggesting that ANXA2
could serve as a new marker for AM diagnosis.
Therefore, changes in the level of ANXA2 should be
monitored clinically to assist the diagnosis and treatment
of patients with AM, so as to grasp their conditions and
predict prognosis changes more accurately. However,
this study needs to be verified by multi-center samples.
REFERENCES
1. Liu LX, Wu YG, Zheng J. Increased annexin A2 and decreased
β-catenin in adenomyosis contribute to adenomyosis-
associated dysmenorrhea. Histol Histopathol 2017;32:11906.
2. Jiang C, Liu C, Guo J. The Expression of Toll-like receptors
in eutopic and ectopic endometrium and its implication in
the inflammatory pathogenesis of adenomyosis. Sci Rep
2017;7(1):7365.
3. Arlıer S, Arıcı A. Tumor necrosis factor alfa and interleukin
1 alfa induced phosphorylation and degradation of inhibitory
This article was originally published in a special issue:
Special issue on “Drug Development and Human Health in
China”
Indian J Pharm Sci 2020:82(1)spl issue2;35-39
This is an open access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike 3.0 License, which
allows others to remix, tweak, and build upon the work non-commercially,
as long as the author is credited and the new creations are licensed under
the identical terms
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.